O também professor da Universidade do Minho esclarece ainda que, “de acordo com as atuais regras da Direção-Geral da Saúde, só são notificados utilizadores com os quais o contacto de risco ocorreu até dois dias antes dos primeiros sintomas da pessoa infetada ou, no caso de assintomática, dois dias antes de efetuar o teste à Covid-19”.
16 novembro 2020
Só 1% dos novos casos são reportados à app Stayaway Covid
Só 1% dos novos casos são reportados à app Stayaway Covid: “Se
o número de códigos fornecidos pelo Sistema
Nacional de Saúde continuar
tão baixo, o impacto da app manter-se-á muito limitado”, admite
Rui
Oliveira, Administrador do Instituto de Engenharia de Sistemas e
Computadores, Tecnologia e Ciência (INESC
TEC),
responsável pelo desenvolvimento da Stayaway
Covid.
Covid vaccine: who is behind the Moderna breakthrough?
Covid vaccine: who is behind the Moderna breakthrough? News that its vaccine candidate – which still has to receive formal approval – is nearly 95% effective
sent global stock markets higher and, coming on top of the similar
recent announcement from the German/US collaboration BioNTech/Pfizer,
injected some much-needed optimism about the possibility of a return to
normal life.
The team behind the Moderna vaccine is led by Tal Zaks, Moderna’s chief medical officer and a former head of global oncology at Sanofi, who said: “This is one of the greatest moments of my life and my career.”
What you need to know about the coronavirus pandemic on 16 November
COVID-19: What you need to know about the coronavirus pandemic on 16 November: Top stories: US confirmed cases pass 11 million; new cases in South Korea cause concern; Italian research suggests coronavirus was circulating much earlier than previously thought.
Rapid Testing Is Less Accurate Than the Government Wants to Admit
Rapid Testing Is Less Accurate Than the Government Wants to Admit: Rapid antigen testing is a mess. The federal government pushed it out without a plan, and then spent weeks denying problems with false positives.
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures: Vaccine candidate now expected to remain stable at standard
refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up
from previous estimate of 7 days
Shipping and long-term storage conditions at standard freezer temperatures of -20°C (-4°F) for 6 months
mRNA-1273 to be distributed using widely available vaccine delivery and storage infrastructure
No dilution required prior to vaccination
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study: The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).
A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the study protocol) in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.
The 95 COVID-19 cases included 15 older adults (ages 65+) and 20 participants identifying as being from diverse communities (including 12 Hispanic or LatinX, 4 Black or African Americans, 3 Asian Americans and 1 multiracial).
'Chumocracy': how Covid revealed the new shape of the Tory establishment
'Chumocracy': how Covid revealed the new shape of the Tory establishment: The anti-establishment claims of a government led by Johnson and Dominic Cummings were always audacious, and in the appointments and contracts awarded during the pandemic, the shape of a Tory establishment has come into focus. Critics are calling it a “chumocracy”.
Subscrever:
Comentários (Atom)
